Grant recipients
In accordance with the grant from the Novo Nordisk Foundation, the Danish Diabetes Academy is allocating co-financed PhD scholarships of each 550.000 DKK, Post Doc fellowships of each 600.000 DKK per year, and a number of Visiting Scientist grants.
The list below features the Danish Diabetes Academy funded PhD and Post Doc fellows, who have received a grant in 2015-2016 and a complete list of Visiting Scientist 2013-2016. Additionally, recipients of exchange travel grants 2016 are featured.
Around 3-10% of patients clinically diagnosed with type 2 diabetes (T2D) have circulating autoantibodies as seen in type 1 diabetes (T1D). This diabetic subtype is termed latent autoimmune diabetes in adults (LADA), and it is the second most common type of diabetes only exceeded in numbers by T2D. Despite the prevalence, LADA is far less studied than its more renowned counterparts T1D and T2D.
The number of people suffering from obesity and obesity-related disorders such as Type 2 Diabetes (T2DM) is increasing worldwide. To break this escalation new therapeutic options are needed. Brown adipose tissue (BAT), also known as brown fat, possesses the ability to “burn” calories by uncoupling the oxidative phosphorylation pathway in the mitochondria.
Fully automated control of blood glucose (BG) level by means of a portable artificial pancreas (AP) will substantially increase the quality of life for type 1 diabetes patients, by reducing the burden of meticulous considerations about manual adjustment of insulin dosage and timing.
Metabolic diseases are global health challenges with a prevalence of individuals with severe overweight and/or type 2 diabetes (T2D) reaching more than 500 million. We are approaching the abyss and thus the need for better and new treatment strategies has never been greater.
Background: Obesity and type 2 diabetes represent a world-wide problem and their treatment is a growing concern. Roux-en-Y gastric bypass surgery (RYGB) is currently the most successful treatment with diabetes remission rates of 50-80 % and weight loss of 30% in obese individuals. Most importantly, mortality is reduced about 30 %. These results show that there are mechanisms within our own body that can cure diabetes and obesity.
Type 2 diabetes is a widespread and escalating disease worldwide. It is associated with a physiological inability to handle glucose, which leads to disease in the heart, vasculature, nerves, kidneys and eyes. Fatty liver disease is also closely related to diabetes.
In vitro produced pancreatic β-cells are a potential source for cell replacement therapies, but in order to produce safe cells for therapeutic purposes the biology underlying β-cell specification should be addressed. The objective of this project is to determine the mechanisms underlying pancreatic endocrine lineage allocation with focus on the principal endocrine lineages involved in glucose homeostasis, the α- and β-cell lineages.